NO20020811L - Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler - Google Patents

Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler

Info

Publication number
NO20020811L
NO20020811L NO20020811A NO20020811A NO20020811L NO 20020811 L NO20020811 L NO 20020811L NO 20020811 A NO20020811 A NO 20020811A NO 20020811 A NO20020811 A NO 20020811A NO 20020811 L NO20020811 L NO 20020811L
Authority
NO
Norway
Prior art keywords
drugs
processes
preparation
carboxamide derivatives
sulfonyl
Prior art date
Application number
NO20020811A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020811D0 (no
Inventor
Reinhard Kirsch
Hans-Ludwig Schaefer
Eugen Falk
Horst Hemmerle
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999141540 external-priority patent/DE19941540C2/de
Priority claimed from DE2000127611 external-priority patent/DE10027611A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20020811D0 publication Critical patent/NO20020811D0/no
Publication of NO20020811L publication Critical patent/NO20020811L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20020811A 1999-09-01 2002-02-19 Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler NO20020811L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999141540 DE19941540C2 (de) 1999-09-01 1999-09-01 Sulfonylcarboxamide zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidämie
DE2000127611 DE10027611A1 (de) 2000-06-06 2000-06-06 Sulfonylcarboxamidderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/008027 WO2001016094A1 (de) 1999-09-01 2000-08-17 Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
NO20020811D0 NO20020811D0 (no) 2002-02-19
NO20020811L true NO20020811L (no) 2002-04-30

Family

ID=26005953

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020811A NO20020811L (no) 1999-09-01 2002-02-19 Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler

Country Status (28)

Country Link
US (2) US6342512B1 (cs)
EP (1) EP1218341B1 (cs)
JP (1) JP4792186B2 (cs)
KR (1) KR20020033778A (cs)
CN (1) CN1372541A (cs)
AR (1) AR025444A1 (cs)
AT (1) ATE302754T1 (cs)
AU (1) AU774071B2 (cs)
BR (1) BR0013727A (cs)
CA (1) CA2383781A1 (cs)
CO (1) CO5190698A1 (cs)
CZ (1) CZ2002767A3 (cs)
DE (1) DE50011035D1 (cs)
DK (1) DK1218341T3 (cs)
EE (1) EE200200095A (cs)
ES (1) ES2246247T3 (cs)
HK (1) HK1048984A1 (cs)
HR (1) HRP20020177A2 (cs)
HU (1) HUP0202472A3 (cs)
IL (1) IL148148A0 (cs)
MX (1) MXPA02001696A (cs)
MY (1) MY133732A (cs)
NO (1) NO20020811L (cs)
PL (1) PL353367A1 (cs)
PT (1) PT1218341E (cs)
RU (1) RU2002107998A (cs)
SK (1) SK2682002A3 (cs)
WO (1) WO2001016094A1 (cs)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112040A1 (de) * 2001-03-14 2002-10-02 Aventis Pharma Gmbh Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
EP1406884A1 (en) 2001-05-11 2004-04-14 Biovitrum Ab Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
DE50212937D1 (de) * 2001-08-22 2008-12-04 Sanofi Aventis Deutschland Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
BR0212158A (pt) 2001-08-31 2004-07-13 Aventis Pharma Gmbh Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
PL212089B1 (pl) * 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
US7223796B2 (en) * 2002-04-11 2007-05-29 Sanofi-Aventis Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7078404B2 (en) * 2002-04-11 2006-07-18 Sanofi-Aventis Deutschland Gmbh Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en) * 2002-06-07 2006-05-23 Aventis Pharma Deutschland Gmbh N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
US7262220B2 (en) * 2002-07-11 2007-08-28 Sanofi-Aventis Deutschland Gmbh Urea- and urethane-substituted acylureas, process for their preparation and their use
RS20050019A (en) * 2002-07-12 2007-09-21 Sanofi - Aventis Pharma Deutschland Gmbh., Heterocyclically substituted benzoylureas,method for their production and their use as medicaments
US20040157922A1 (en) * 2002-10-04 2004-08-12 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en) * 2002-10-12 2007-04-24 Sanofi-Aventis Deutschland Gmbh Bicyclic inhibitors of hormone sensitive lipase
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7179941B2 (en) * 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7196114B2 (en) * 2003-02-17 2007-03-27 Sanofi-Aventis Deutschland Gmbh Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) * 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7173151B2 (en) * 2003-02-27 2007-02-06 Sanofi-Aventisdeutschand Gmbh Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) * 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7501440B2 (en) * 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) * 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) * 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) * 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
US7241787B2 (en) * 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) * 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
JP4904026B2 (ja) * 2004-08-04 2012-03-28 日本曹達株式会社 光反応性有機薄膜を形成する新規化合物及び有機薄膜形成体
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
JP5548869B2 (ja) 2006-03-17 2014-07-16 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 新規で生理学的に有用なニトロキシル供与体としてのn−ヒドロキシルスルホンアミド誘導体
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP4891111B2 (ja) * 2007-02-16 2012-03-07 富士フイルム株式会社 ズームレンズ
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
CA2699152C (en) 2007-09-12 2015-11-24 Activx Biosciences, Inc. Spirocyclic aminoquinolones as gsk-3 inhibitors
WO2009042970A1 (en) * 2007-09-26 2009-04-02 Johns Hopkins University N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2406266B1 (en) 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US20120270819A1 (en) 2009-10-02 2012-10-25 Sanofi Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone disease
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6103182B2 (ja) * 2011-10-03 2017-03-29 セイコーエプソン株式会社 発電装置、電子機器、移動手段及び発電装置の制御方法
FR2997247B1 (fr) * 2012-10-22 2016-12-09 Commissariat Energie Atomique Generateur d'electricite et recuperateur d'energie
CN104502513B (zh) * 2015-01-14 2016-04-06 中国矿业大学连云港徐圩新区高新技术研究院 一种对羧基苯磺酰胺的高效液相色谱测定方法
EP3896066A3 (de) * 2015-08-07 2021-12-08 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138399A (en) 1970-09-14 1979-02-06 Pfizer Inc. Sulfamylbenzoic acid
GB1353357A (en) * 1970-09-14 1974-05-15 Pfizer Substituted 5-sulphamylbenzoic acids
DE2517183A1 (de) * 1975-04-18 1976-10-28 Hoechst Ag Basisch substituierte 5-sulfamoyl- anthranilsaeurederivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
RU2002107998A (ru) 2003-11-10
DE50011035D1 (de) 2005-09-29
CZ2002767A3 (cs) 2002-06-12
MY133732A (en) 2007-11-30
ATE302754T1 (de) 2005-09-15
MXPA02001696A (es) 2002-08-06
AR025444A1 (es) 2002-11-27
PT1218341E (pt) 2005-11-30
WO2001016094A1 (de) 2001-03-08
US6552048B2 (en) 2003-04-22
SK2682002A3 (en) 2002-07-02
AU774071B2 (en) 2004-06-17
US20020072520A1 (en) 2002-06-13
AU6571200A (en) 2001-03-26
CN1372541A (zh) 2002-10-02
HUP0202472A2 (hu) 2002-12-28
JP4792186B2 (ja) 2011-10-12
IL148148A0 (en) 2002-09-12
NO20020811D0 (no) 2002-02-19
JP2003508380A (ja) 2003-03-04
KR20020033778A (ko) 2002-05-07
CO5190698A1 (es) 2002-08-29
HK1048984A1 (zh) 2003-04-25
EE200200095A (et) 2003-04-15
HUP0202472A3 (en) 2005-03-29
US6342512B1 (en) 2002-01-29
EP1218341A1 (de) 2002-07-03
CA2383781A1 (en) 2001-03-08
HRP20020177A2 (en) 2004-02-29
BR0013727A (pt) 2002-05-07
PL353367A1 (en) 2003-11-17
ES2246247T3 (es) 2006-02-16
EP1218341B1 (de) 2005-08-24
DK1218341T3 (da) 2005-12-12

Similar Documents

Publication Publication Date Title
NO20020811L (no) Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20052802L (no) Pyrrolopyrimidinderivativer
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
NO20061743L (no) Kinazolinderivater
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2004005286A3 (en) Viral inhibitors
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
TNSN06030A1 (en) Substituted thiazole-benzoisothiazole dioxide derivavites, method for the production thereof and use of the same
WO2004067550A3 (fr) Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
NO20063382L (no) Nye kinolinderivater
NO20090749L (no) Arylaminoaryl-alkyl-substituerte imidazolidin-2,4-dioner, fremgangsmate for fremstilling derav, medikamenter inneholdende forbindelsene og deres anvendelse
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
NO20050073L (no) Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene
EP1396493A4 (en) HETEROCYCLIC COMPOUNDS
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
NO330888B1 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling av slike, terapeutisk preparatinneholdende slike samt anvendelse av slike for fremstilling av preparat for behandling av sykdom
NO20070570L (no) Forbindelser.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application